__NUXT_JSONP__("/drugs/Busulfan", (function(a,b,c,d,e,f){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.",inn:b,marketingAuthorisationDate:"2014-09-22 00:00:00",marketingAuthorisationHolder:"Fresenius Kabi Deutschland GmbH",medicineName:"Busulfan Fresenius Kabi",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fbusulfan-fresenius-kabi"},{activeSubstance:b,conditionIndication:"Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busilvex following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.",inn:b,marketingAuthorisationDate:"2003-07-09 00:00:00",marketingAuthorisationHolder:"Pierre Fabre Médicament",medicineName:"Busilvex",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fbusilvex"}],fdaDrugLabel:[{brand:d,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1)",manufacturer:"American Regent, Inc.",splSetId:"060db20b-d889-48db-a034-83dc3811d723"},{brand:a,indication:c,manufacturer:"Sagent Pharmaceuticals",splSetId:"086a715e-4958-4bb5-9ebd-86171e6b6203"},{brand:a,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )",manufacturer:"CELLTRION USA, INC.",splSetId:"3ab9b45c-b63a-4152-a242-4f218c520b3b"},{brand:a,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). ( 1 )",manufacturer:"Armas Pharmaceuticals Inc.",splSetId:"4049d57f-342e-4233-8292-fed6b8f128ec"},{brand:"BUSULFEX",indication:"1 INDICATIONS AND USAGE BUSULFEX is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )",manufacturer:"Otsuka America Pharmaceutical, Inc.",splSetId:"5cb9d285-1803-4a99-946a-d0b239b32df6"},{brand:a,indication:"1. INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )",manufacturer:"Fresenius Kabi USA, LLC",splSetId:"65df3357-2549-466f-96c0-ea35365626a9"},{brand:a,indication:c,manufacturer:e,splSetId:"6e68ab21-19bd-4b7e-b8d0-bf284d5af183"},{brand:a,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is an alkylating drug indicated for: • Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )",manufacturer:"Mylan Institutional LLC",splSetId:"9955aced-ac32-43e6-b39a-c6c023a50dc3"},{brand:a,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: • Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )",manufacturer:"Apotex Corp.",splSetId:"a67d61d4-f985-e653-5343-b49d17784b3c"},{brand:a,indication:"1 INDICATIONS AND USAGE Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). (1)",manufacturer:"Amneal Pharmaceuticals LLC",splSetId:"ac9448da-37ad-4609-9aef-eedf8be0f69c"},{brand:d,indication:"1 INDICATIONS AND USAGE Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). ( 1 )",manufacturer:"Hospira, Inc.",splSetId:"b9c7f0dc-988d-466e-8031-400ec4f60f21"},{brand:"MYLERAN",indication:"INDICATIONS AND USAGE MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.",manufacturer:"Aspen Global Inc.",splSetId:"bf456fc7-3a79-47f7-8acc-600b5e2f0dc2"},{brand:a,indication:c,manufacturer:"Pharmascience Inc.",splSetId:"d0fe44f9-7747-4909-b927-3b24aa6e7e09"},{brand:a,indication:c,manufacturer:e,splSetId:"dc384f16-4e25-458e-874c-553f81c6d8c9"},{brand:a,indication:c,manufacturer:"Accord Healthcare, Inc",splSetId:"fe0ddd44-ef02-4827-b164-7fcbb45bcc1b"}],id:a,nciThesaurus:{casRegistry:"55-98-1",chebiId:"CHEBI:28901",chemicalFormula:"C6H14O6S2",definition:"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription.",fdaUniiCode:"G1LN9045DK",identifier:"C321",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C222"],synonyms:["1, 4-Bis[methanesulfonoxy]butane","1,4-Bis(methanesulfonoxy)butane","1,4-Bitanediol Dimethanesulfonate Esters","1,4-Butanediol Dimethylsulfonate","1,4-Di(methanesulfonyloxy)butane","1,4-Di(methylsulfonyloxy)butane","BUS",d,"Bussulfam",a,"Busulfanum","Busulfex","Busulphan","CB 2041","CB-2041","GT 41","GT-41","Glyzophrol","Joacamine","Methanesulfonic Acid Tetramethylene Ester","Methanesulfonic acid, tetramethylene ester","Mielucin","Misulban","Misulfan","Mitosan","Myeleukon","Myeloleukon","Myelosan","Mylecytan","Myleran","Sulfabutin","Tetramethylene Bis(methanesulfonate)","Tetramethylene bis[methanesulfonate]","WR-19508",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FBusulfan",extension:".json",createdAt:f,updatedAt:f}}],fetch:{},mutations:void 0}}("Busulfan","busulfan","1 INDICATIONS AND USAGE Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) ( 1 )","BUSULFAN","Meitheal Pharmaceuticals Inc.","2021-10-30T13:39:16.973Z")));